You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

August 10, 2026

Vietnam’s New Drug Registration Regulations to Reduce Administrative Burden

Subscribe to Updates

The drug registration process in Vietnam will be simplified, particularly for foreign applicants, following the recent issuance by Vietnam’s Ministry of Health (MOH) of a new circular that is expected to reduce administrative hurdles. Circular No. 32/2026/TT-BYT on the registration of drugs and medicinal ingredients (Circular 32) was issued on July 29, 2026, and will take effect on October 1, 2026, replacing Circular No. 12/2025/TT-BYT.

Key provisions of the new circular are discussed below.

Five-Year Data Exclusivity and Five-Month Public Disclosure Framework

Circular 32 updates data protection guidelines by explicitly referencing Article 128 of the amended Intellectual Property Law, which sets out that new drugs supported by clinical trial data submitted for the first time will be granted a five-year data exclusivity period from the date of the initial marketing authorization (MA) approval. Subsequent applications that rely on the originator’s protected data will not be eligible for approval from the date of submission of the originator’s registration dossier until five years after the first MA is granted.

Furthermore, in accordance with the new regulations, the regulatory authority must publicly disclose information on subsequent applications five months before the granting of MA, providing originator companies with an opportunity to exercise and enforce their intellectual property rights.

Simplified Requirements for Foreign Legal Documents

Circular 32 expands the circumstances under which legal documents issued by foreign authorities are exempt from consular legalization and authenticity verification requirements. Specifically, such documents may be exempt if the Drug Administration of Vietnam (DAV) is able to verify their authenticity directly through official electronic means, including written confirmation or email correspondence sent directly to the MOH by the competent foreign authority, or publicly accessible English-language databases maintained by recognized foreign regulatory authorities.

In addition, the new circular permits the submission of electronic notarized copies of legal documents in registration dossiers as an alternative to hard-copy notarized documents.

Detailed Regulations on CEPs

Circular 32 provides more detailed requirements regarding the submission of electronic CEPs (“certification of suitability to the monographs of the European Pharmacopoeia”) within quality dossiers.

  • For CEPs issued prior to September 1, 2023: The CEP must bear the official stamp/confirmation of the finished product manufacturer or applicant, and the CEP authorization section must explicitly list the authorized applicant or manufacturer.
  • For CEPs issued from September 1, 2023, onward: A valid electronic CEP bearing an EDQM (European Directorate for the Quality of Medicines & HealthCare) digital signature, accompanied by an authorization letter must be submitted.

Applicants must also provide the results of a self-search conducted in the EDQM database, including mandatory information such as name of medicinal ingredient, CEP holder information, monograph number, and validity status.

Flexibility and Deferral of CPP Submissions

For new drugs and certain specified cases, applicants may postpone submission of a Certificate of Pharmaceutical Product (CPP) at the time of initial dossier filing by providing a written justification explaining its absence. However, the CPP must be submitted no later than the second round of dossier supplementation in order for the application to remain eligible for MA approval.

Exemption from Legal Documents for Pharmaceutical Ingredients with Granted MA

Where a finished product uses pharmaceutical ingredients that have already been granted MA in Vietnam, and strictly complies with the approved information (including ingredient name, manufacturer, specifications, and source), applicants are exempt from submitting legal documents demonstrating GMP compliance for ingredient manufacturers.

The applicant only needs to submit two certificates of analysis (COAs) for the ingredient—one issued by the ingredient manufacturer and one issued by the finished product manufacturer.

Detailed Implementation Rules for Post-Approval Variations

Under Circular 32, minor variations requiring notification (MiV-N) may be implemented immediately upon receipt of the notification dossier by the DAV or, at the latest, within 12 months from the date of public disclosure of the variation.

For imported drugs and medicinal ingredients, products may continue to be imported and circulated until their expiry date, provided they were dispatched from the port of export before the mandatory implementation deadline.

New Re-examination Pathway

Upon receiving an official refusal decision for a new registration, renewal, or variation application, applicants will have one month to submit a written explanation requesting reconsideration. If the explanation is accepted by the Advisory Council for granting MA or designated experts, the application may be approved directly without requiring the applicant to prepare and submit a completely new dossier. This new re-examination mechanism is expected to reduce the administrative burden, shorten approval timelines, and improve overall regulatory efficiency.

Next Steps

Pharmaceutical companies should review the new provisions for any potential impacts on current and future registration strategies to ensure timely compliance ahead of the circular’s effective date of October 1, 2026.

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

November 4, 2021
A new royal decree in Thailand (Royal Decree Re: Licensee to Pay the License Renewal Fee in Lieu of a Grace Period When Submitting a License Renewal Application B.E. 2564) does away with the current red tape associated with renewing certain marketing authorization and business licenses. Under the new royal decree, there is no longer any need to submit renewal applications for eligible licenses or to wait for approval from the relevant authority. Instead, the licenses will be automatically renewed upon payment of renewal fees. There are 31 eligible licenses listed in the royal decree, with a focus on licenses for hazardous substances and cosmetics. The royal decree on license renewal was published in the Government Gazette in May 2021 and will come into force on November 22, 2021. Although the new royal decree has not yet come into force, Thailand’s Food and Drug Administration (FDA) has already begun renewing licenses for hazardous substance licenses and cosmetics notification receipts via the new procedure. These licenses and notification receipts are detailed below: (Note: Hazardous substances for household use and public health are classified into four types according to their risk. Products containing type 2 and 3 substances are a higher risk than type 1 and must be registered with the FDA. Type 4 substances are prohibited.) Procedural Guidance The licenses for hazardous substances in the table above should be renewed in the two months preceding their expiry date, while the notification receipts for cosmetics should be renewed in the six months before their expiry date. Renewed licenses are valid for another six or three years (i.e., matching the original validity period). Under the new royal decree on license renewal, eligible licenses for hazardous substances and cosmetics can be renewed by notifying the FDA via its e-submission system. The license holder
Read More
October 26, 2021
Parallel imports—branded goods imported into a domestic market and sold there without the consent of the intellectual property (IP) owner—pose a unique challenge for IP owners. In contrast to counterfeit goods, parallel imported goods are manufactured by or under the license of the IP owner and formulated or packaged for a particular jurisdiction and then imported into a different jurisdiction without the authorization of the IP owner. Intellectual property laws and perspectives on parallel import vary throughout Southeast Asia. The distinct legal landscape in each nation should be carefully navigated in consultation with legal experts to ensure brand protection to the fullest degree. This guide provides insight into the legal frameworks relating to parallel imports in Cambodia, Indonesia, Laos, Myanmar, Thailand, and Vietnam. Each section examines the relevant laws and regulations that pertain to parallel imports and explores the remedies available to IP owners in each country. Finally, the guide presents some strategies to combat parallel importation and maximize IP protection in Southeast Asia. The full guide can be downloaded through the button below.   This guide was prepared with the assistance of Tilleke & Gibbins interns Christian Pederson and Keoni Williams.
Read More
October 25, 2021
Michael Ramirez, a counsel in Tilleke & Gibbins’ dispute resolution group in Bangkok, has updated the firm’s contribution to the Global Attorney-Client Privilege Guide, published by Lex Mundi. The newly expanded guide provides information on what constitutes attorney-client privilege in over 70 countries around the world. The Thailand section of the guide contains in-depth information on the function and applications of attorney-client privilege in Thailand (or, as explained in the guide, an equivalent concept enshrined in Thai law), including coverage of the following topics: Privilege in corporations Common interest doctrine Litigation funding Crime-fraud exception Work product doctrine/litigation privilege Other privileges including mediation, accountant-client and settlement negotiation The interactive guide features expert contributions by Lex Mundi member firms from jurisdictions worldwide. Readers can browse the contributions, generate country-specific reports, and compare attorney-client privilege in multiple jurisdictions. For more information, please visit the Lex Mundi website.
Read More
October 14, 2021
As part of its membership in Lex Mundi, Tilleke & Gibbins has published an updated edition of its Guide to Doing Business in Thailand for 2021. This guide outlines all of the key factors for starting and operating a business in the Thai market. Issues covered include: Investment incentives Financial facilities Exchange controls Import and export regulations Structures for doing business Requirements for the Establishment of a Business Operation of the Business Cessation or Termination of the Business Labor legislation, relations, and supply Tax Immigration requirements This publication is part of Lex Mundi’s Guides to Doing Business series prepared by member firms in more than 100 jurisdictions worldwide. The guides serve as a useful resource when planning an international business strategy or researching a new market.
Read More